PMID- 38138178
OWN - NLM
STAT- MEDLINE
DCOM- 20231225
LR  - 20231225
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 59
IP  - 12
DP  - 2023 Nov 24
TI  - An Exploratory Retrospective Data Analysis Comparing the Outcomes of Selective 
      Laser Trabeculoplasty and Argon Laser Trabeculoplasty in Patients with Open-Angle 
      Glaucoma or Ocular Hypertension in Vienna, Austria, from the Year 2012 to 2022.
LID - 10.3390/medicina59122075 [doi]
LID - 2075
AB  - Background and Objectives: The aim of the present study was to compare the 
      short-term outcomes of selective laser trabeculoplasty (SLT) with argon laser 
      trabeculoplasty (ALT) in patients with glaucoma in a real-world setting. 
      Materials and Methods: The present study was conducted as a retrospective 
      case-control study. The main outcome was the change in intraocular pressure (IOP) 
      three months after laser surgery. In addition, the number of substances used for 
      lowering of IOP and adverse events (AEs) were assessed. Results: Charts from 25 
      patients were included in the present study, of which 12 had received ALT and 13 
      SLT. In both groups, IOP significantly decreased from baseline values 6 weeks and 
      3 months after laser treatment (p < 0.01 vs. baseline at each timepoint for both 
      groups). While after 6 weeks, no difference between groups was found, after 3 
      months, the decrease in IOP was significantly more pronounced in the SLT group 
      (-26 +/- 21% in the ALT group vs. -41 +/- 14% in the SLT group, p = 0.018 between 
      groups, ANOVA). Three months after laser treatment, the number of IOP-lowering 
      substances used by each patient had decreased with no difference between groups 
      (ALT: from 2.7 +/- 0.8 to 2.3 +/- 0.9 substances; SLT: from 1.8 +/- 1.2 to 1.3 +/- 1.1 
      substances, p = 0.386). Only a few AEs were observed. Two patients in the ALT and 
      one patient in the SLT group required trabeculectomy within 1 year after laser 
      treatment due to IOP decompensation. Conclusions: In the present study, SLT was 
      at least as effective as ALT with fewer AEs and a similar reduction in 
      concomitant IOP-lowering medication.
FAU - Schmidl, Doreen
AU  - Schmidl D
AUID- ORCID: 0000-0001-5664-7768
AD  - Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, 
      Austria.
FAU - Hommer, Nikolaus
AU  - Hommer N
AUID- ORCID: 0000-0002-4116-1359
AD  - Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, 
      Austria.
AD  - Hommer Ophthalmology Institute, Albertgasse 39, 1080 Vienna, Austria.
AD  - Department of Ophthalmology, Hanusch Hospital, 1140 Vienna, Austria.
FAU - Hommer, Anton
AU  - Hommer A
AD  - Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, 
      Austria.
AD  - Hommer Ophthalmology Institute, Albertgasse 39, 1080 Vienna, Austria.
AD  - Department of Ophthalmology, Hera Hospital, 1090 Vienna, Austria.
LA  - eng
GR  - NA/Nidek (Japan)/
PT  - Journal Article
DEP - 20231124
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 67XQY1V3KH (Argon)
SB  - IM
MH  - Humans
MH  - *Trabeculectomy
MH  - *Glaucoma, Open-Angle/surgery
MH  - Argon
MH  - Retrospective Studies
MH  - Case-Control Studies
MH  - Austria
MH  - Treatment Outcome
MH  - *Glaucoma/surgery
MH  - *Ocular Hypertension/surgery
MH  - Intraocular Pressure
MH  - *Laser Therapy
MH  - Lasers
PMC - PMC10744835
OTO - NOTNLM
OT  - Vienna
OT  - argon laser trabeculoplasty (ALT)
OT  - glaucoma
OT  - retrospective
OT  - selective laser trabeculoplasty (SLT)
COIS- D.S. and A.H. are consultants and received speaker fees from NIDEK Co., Ltd. The 
      funder had no role in the design of the study; in the collection, analyses, or 
      interpretation of data; in the writing of the manuscript; or in the decision to 
      publish the results.
EDAT- 2023/12/23 12:43
MHDA- 2023/12/25 06:42
PMCR- 2023/11/24
CRDT- 2023/12/23 01:14
PHST- 2023/09/06 00:00 [received]
PHST- 2023/11/21 00:00 [revised]
PHST- 2023/11/22 00:00 [accepted]
PHST- 2023/12/25 06:42 [medline]
PHST- 2023/12/23 12:43 [pubmed]
PHST- 2023/12/23 01:14 [entrez]
PHST- 2023/11/24 00:00 [pmc-release]
AID - medicina59122075 [pii]
AID - medicina-59-02075 [pii]
AID - 10.3390/medicina59122075 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2023 Nov 24;59(12):2075. doi: 10.3390/medicina59122075.